CARDIAC FAILURE CONGESTIVE and Norco

PatientsVille

Find and Compare Side Effects

CARDIAC FAILURE CONGESTIVE Symptoms and Causes

Heartfailure is a condition in which the heart can't pump enough blood to meet the body's needs. Heartfailure does not mean that your heart has stopped or is about to stop working. It means that your heart is not able to pump blood the way it should. It can affect one or both sides of the heart.

The weakening of the heart's pumping ability causes

Blood and fluid to back up into the lungs

The buildup of fluid in the feet, ankles and legs - called edema

Tiredness and shortness of breath

Common causes of heartfailure are coronary artery disease, high blood pressure and diabetes. It is more common in people who are 65 years old or older, African Americans, people who are overweight, and people who have had a heart attack. Men have a higher rate of heartfailure than women.

Your doctor will diagnose heartfailure by doing a physical exam and heart tests. Treatment includes treating the underlying cause of your heartfailure, medicines, and heart transplantation if other treatments fail.

CARDIAC FAILURE CONGESTIVE Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.

To compare the occurrence and severity of opioid-induced nausea and vomiting (OINV) associated with CL-108 to Norco.; To demonstrate the efficacy of CL-108 when compared to placebo for the relief of pain following surgical removal of impacted third molar teeth.; Reduction of the severity of nausea in patients treated with an opioid-containing pain reliever.; Reduction of vomiting in patients treated with an opioid-containing pain reliever.

Drug: Morphine PCA started at the end of surgery, 1 Percocet 1/325mg every 4 hours; may receive a second Percocet if needed.; Drug: For the 30ml ropivacaine the intervention would be the subject can request extra pain medication which would be Percocet and/or morphine PCA.

To estimate the prevalence and histologic spectrum of liver injury in an adult with Alpha-1 Antitrypsin deficiency and a genotype of ZZ.; To identify environmental and host risk factors for clinically significant liver fibrosis.; To define the diagnostic accuracy of non-invasive markers of fibrosis in AAT liver disease.; To explore epigenetic markers for the development of liver fibrosis.; To quantify liver fibrosis progression.

If you think you may have a medical emergency, call your doctor or 911 immediately.

By accessing this website, you are indicating your acknowledgement and acceptance of these Terms of Use. These Terms of Use are subject to change by WinFirst LLC at any time in its discretion. Your use of WinFirst LLC Site after such changes are implemented constitutes your acknowledgement and acceptance of the changes. Please consult these Terms of Use regularly.
PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.